Pharmaceutical Options for Stress Urinary Incontinence

AbstractPurpose of ReviewWe review the currently available pharmaceutical options for SUI.Recent FindingsPharmaceutical options for SUI are either drugs that manipulate hormones or those that impact neurotransmitter levels. Local estrogen replenishment has been associated with improved OAB symptoms in postmenopausal women, but its impact on SUI is unclear. Subjective improvement may be noted, while objective outcome indices are typically unchanged. There is weak evidence to suggest that any adrenergic agonist is better than placebo in improving objective incontinence measures. Both alpha- and beta-adrenergic agonists are associated with significant side effects. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has been shown to improve both objective and subjective outcome indices, but it is associated with significant side effects and is not FDA-approved. Evidence for the use of TAS-303, a norepinephrine reuptake inhibitor, is currently in the early stages and its clinically significant improvement and durability are unknown at this time. Finally, selective androgen receptor modulators (SARM) have shown promise in both animal and early human studies; however, a preliminary report from a large, multi-institutional, placebo-controlled trial of one of these agents (enobosarm reported that this drug did not achieve statistical significance in its primary endpoint compared to placebo. Overall, the drug was well tolerated.SummaryThe majority of drugs available...
Source: Current Bladder Dysfunction Reports - Category: Urology & Nephrology Source Type: research